LitAlert ~~ GeneLit.com

    • Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
    • Samusieva A, Serga S, Klymenko S, Rybchenko L, Klimuk B, Zakhartseva L, Gorovenko N, Lobanova O, Rossokha Z, Fishchuk L, Levkovich N, Medvedieva N, Popova O, Cheshuk V, Inomistova M, Khranovska N, Skachkova O, Michailovich Y, Ponomarova O, Kozeretska I
    • Breast Cancer Res Treat. 2022 Aug 5. doi: 10.1007/s10549-022-06692-3. Epub ahead of print.
    • Preclinical characterization of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper.
    • Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkil J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E.
    • Clin Cancer Res. 2022 Aug 5:ccr.22.0301. doi: 10.1158/1078-0432.CCR-22-0301. Epub ahead of print.

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: a focus on the immune system.
    • Bound NT, Vandenberg CJ, Kartikasari A, Plebanski M, Scott CL.
    • Front Genet. 2022 Aug 5;12:886170. doi: 10.3389/fgene.2022.886170.
    • Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
    • Bhatt A, Bhandoria G, Kepenekian V, Bakrin N, Glehen O.
    • Int J Cancer. 2022 Aug 5. doi: 10.1002/ijc.34220. Epub ahead of print.
    • Comment. Letter.

    Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    Original research:

    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.

    • Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
    • Brewer T, Yehia L, Bazeley P, Eng C.
    • Am J Hum Genet. 2022 Aug 4;109(8):1520-1533. doi: 10.1016/j.ajhg.2022.07.005. Epub 2022 Aug 4.

    Research news: PTEN Mutation Syndrome Leads to Breast Cancers With Distinct Molecular Alterations. (GenomeWeb)

    • Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
    • Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes AM, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodriguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow SE, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan EB, Lord CJ, Cruz C, Balmaña J, O'Connor MJ.
    • Clin Cancer Res. 2022 Aug 3:CCR-22-0568. doi: 10.1158/1078-0432.CCR-22-0568. Epub ahead of print.
    • What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    • Moss KM, Mishra GD, Krejany EO, Hickey M.
    • Gynecol Oncol. 2022 Aug 3:S0090-8258(22)00513-3. doi: 10.1016/j.ygyno.2022.07.029. Epub ahead of print.